Using atypical antipsychotics increases risk of sudden cardiac death in adults
Patients ages 30 to 74 who took atypical antipsychotics
such as risperidone, quetiapine, olanzapine and clozapine had a significantly
higher risk of sudden death from cardiac arrhythmias and other cardiac causes
than patients who did not take these medications, according to a new study funded
by HHS' Agency for Healthcare Research and Quality. The risk of death increased
with higher doses of the drugs taken.
The study, titled "Atypical Antipsychotic Drugs
and the Risk of Sudden Cardiac Death," is published in the January 15 issue
of the New England Journal of Medicine.
Atypical antipsychotics are commonly used to treat schizophrenia
and bipolar disorders. They are also prescribed "off label" for symptoms such
as agitation, anxiety, psychotic episodes and obsessive behaviors. Atypical antipsychotics
are less likely to cause tremors and other serious movement disorders that affect
users of typical antipsychotics. "This study provides critical information about
the safety of atypical antipsychotics that can be used to make important treatment
decisions for patients," said AHRQ Director Carolyn M. Clancy, M.D. "These findings
will help clinicians and patients weigh the risks versus the benefits of these
drugs before prescribing them for treatment of depression or other off label uses
for other conditions."
Lead researcher Wayne A. Ray, Ph.D., and his colleagues
at AHRQ's Center for Education and Research on Therapeutics at Vanderbilt University
in Nashville found that current users of atypical antipsychotic drugs had a rate
of sudden cardiac death twice that of people who didn't use the drugs and similar
to the death rate for patients taking typical antipsychotics, including haloperidol
and thioridazine.
Researchers reviewed medical records from the Tennessee
Medicaid program and identified data on patients prescribed atypical antipsychotics,
including the number of prescriptions they received, the dose and the number of
days supplied. Researchers conclude that atypical antipsychotics are not a safer
alternative to typical antipsychotics in preventing death from sudden cardiac
causes.
|